Yahne v. A1A Inc

CourtDistrict Court, W.D. Washington
DecidedApril 4, 2023
Docket2:22-cv-01406
StatusUnknown

This text of Yahne v. A1A Inc (Yahne v. A1A Inc) is published on Counsel Stack Legal Research, covering District Court, W.D. Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Yahne v. A1A Inc, (W.D. Wash. 2023).

Opinion

6 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON 7 AT SEATTLE 8

9 LINDA YAHNE, et al., Case No. C22-01406 RSM

10 Plaintiffs, ORDER GRANTING PLAINTIFFS’ 11 MOTION TO REMAND v. 12 13 A1A, INC., et al.,

14 Defendants. 15

16 I. INTRODUCTION 17 This matter comes before the Court on Plaintiffs’ Motion to Remand. Dkt. #13. 18 Defendants oppose Plaintiffs’ motion to remand on the basis that Plaintiffs fraudulently joined 19 in-state Defendants and that Plaintiffs’ claims are preempted by federal law. Dkt. #17. The 20 Court has determined that it can rule on this Motion without oral argument. For the reasons 21 22 below, the Court GRANTS Plaintiffs’ Motion and REMANDS this case to King County Superior 23 Court. 24 II. BACKGROUND 25 This case involves the alleged failure of a DePuy Pinnacle hip replacement (“Pinnacle 26 27 Device”) implanted in the bodies of Plaintiffs. In their Complaint filed in state court on 28 September 1, 2022, Plaintiffs asserted claims against all Defendants for failure to warn, negligent misrepresentation, violations of the Washington Consumer Protection Act, and breach of 1 2 warranty. See Dkt. #1-2. Plaintiffs asserted an additional claim of negligence against Defendants 3 A1A, Inc. and David Tully Eva (“Distributor Defendants”). Id. ¶¶ 288–94. Additionally, 4 Plaintiffs alleged claims of strict liability and negligence against Defendants Medical Device 5 Business Services, Inc., DePuy Synthes Sales Inc., Johnson & Johnson Services, Inc., and 6 Johnson & Johnson (“J&J Defendants”). 7 8 On October 3, 2022, J&J Defendants removed the case to federal court on the basis of 9 diversity jurisdiction. Dkt #1 at 3. Recognizing that Distributor Defendants, like Plaintiffs, are 10 citizens of Washington, J&J Defendants assert that Distributor Defendants are fraudulently 11 joined and their citizenship should be disregarded for purposes of determining whether removal 12 13 is proper. Id. at 4. In support, J&J Defendants argue that Plaintiffs’ claims against Distributor 14 Defendants have “no possibility of success.” Id. J&J Defendants additionally argue that even if 15 these claims are cognizable under state law, “such claims against non-manufacturers of an FDA- 16 cleared product are preempted” by federal law. Id. at 12. 17 On October 20, 2022, Plaintiffs filed the instant motion claiming J&J Defendants had no 18 19 basis for invoking federal jurisdiction because J&J Defendants (1) cannot meet their burden of 20 proving fraudulent joinder; and (2) their theory of federal preemption does not apply in claims 21 against medical devices. Dkt. #13 at 7, 16. Plaintiffs contend that their claims against Distributor 22 Defendants have a possibility of success, and therefore this case must be remanded. Id. at 6. 23 III. DISCUSSION 24 25 A. Legal Standard 26 When a case is filed in state court, removal is typically proper if the complaint raises a 27 federal question or where there is diversity of citizenship between the parties and the amount in 28 controversy exceeds $75,000. 28 U.S.C. §§ 1331, 1332(a). “A party may remove any claim or 1 2 cause of action in a civil action . . . to the district court for the district where such civil action is 3 pending, if such district court has jurisdiction of such claim or cause of action under section 1334 4 of this title.” 28 U.S.C. § 1452(a). Typically, it is presumed “‘that a cause lies outside [the] 5 limited jurisdiction [of the federal courts] and the burden of establishing the contrary rests upon 6 the party asserting jurisdiction.’” Hunter v. Philip Morris USA, 582 F.3d 1039, 1042 (9th Cir. 7 8 2009). Courts “strictly construe the removal statute against removal jurisdiction.” Gaus v. Miles, 9 Inc., 980 F.2d 564, 566 (9th Cir. 1992). 10 Fraudulent joinder must be proven by clear and convincing evidence. Hamilton 11 Materials, Inc. v. Dow Chem. Corp., 494 F.3d 1203, 1206 (9th Cir. 2007). The party charging 12 13 fraudulent joinder bears the “heavy burden” of showing that the complaint “obviously fails” to 14 state a claim. Hunter v. Philip Morris USA, 582 F.3d 1039, 1044 (9th Cir. 2009). The removing 15 defendant is entitled to present facts outside of the complaint to establish that a party has been 16 fraudulently joined. McCabe, 811 F.2d at 1339. Doubt concerning whether the complaint states 17 a cause of action is resolved in favor of remanding the case to state court. Albi v. Street & Smith 18 19 Publications, 140 F.2d 310, 312 (9th Cir. 1944). 20 There are two ways to establish fraudulent joinder: “(1) actual fraud in the pleading of 21 jurisdictional facts, or (2) inability of the plaintiff to establish a cause of action against the non- 22 diverse party in state court.” Hunter v. Philip Morris USA, 582 F.3d 1039, 1044 (9th Cir. 2009) 23 (quoting Smallwood v. Illinois Cent. RR. Co., 385 F.3d 568, 573 (5th Cir. 2004)). Fraudulent 24 25 joinder is established the second way if a defendant shows that an “individual[ ] joined in the 26 action cannot be liable on any theory.” Ritchey v. Upjohn Drug Co., 139 F.3d 1313, 1318 (9th 27 Cir. 1998). But “if there is a possibility that a state court would find that the complaint states a 28 cause of action against any of the resident defendants, the federal court must find that the joinder 1 2 was proper and remand the case to the state court.” Hunter, 582 F.3d at 1046 (quoting Tillman v. 3 R.J. Reynolds Tobacco, 340 F.3d 1277, 1279 (11th Cir. 2003) (per curiam)) (emphasis added). 4 B. Analysis 5 1. Remand is Proper Because No Diversity Jurisdiction Exists 6 As noted above, Plaintiffs’ Complaint alleges multiple state law claims, including a 7 8 claim under the Washington Product Liability Act (“WPLA”), against state defendants. See 9 Dkt. #1-2. J&J Defendants argue there is no possibility that Plaintiffs can prevail against the 10 Distributor Defendants on these state law claims, and even if Plaintiffs have adequately pled 11 these claims, the claims are preempted by federal law. See Dkt. #17. 12 13 J&J Defendants argue that PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011) and Mut. 14 Pharm. Co. v. Bartlett, 570 U.S. 472 (2013) preempt Plaintiffs’ state law claims against 15 Distributor Defendants. Dkt. #17 at 14–18. As the court explained in Hunter v. Philip Morris 16 USA, 582 F.3d 1039, 1045, a determination of the preemption defense is inappropriate during a 17 fraudulent joinder inquiry. The preemption question requires a court in inquire into the merits 18 19 of the plaintiff’s case. Hunter, 582 F.3d at 1045. Such an inquiry should be “brought in the 20 context of attacking the merits of [plaintiff’s] case, rather than as a basis for removing the case 21 to federal court.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Tillman v. R. J. Reynolds Tobacco
340 F.3d 1277 (Eleventh Circuit, 2003)
Martin v. Franklin Capital Corp.
546 U.S. 132 (Supreme Court, 2005)
Hunter v. Philip Morris USA
582 F.3d 1039 (Ninth Circuit, 2009)
Lussier v. Dollar Tree Stores, Inc.
518 F.3d 1062 (Ninth Circuit, 2008)
Hamilton Materials, Inc. v. Dow Chemical Corp.
494 F.3d 1203 (Ninth Circuit, 2007)
Albi v. Street & Smith Publications, Inc.
140 F.2d 310 (Ninth Circuit, 1944)
Grancare v. Ruth Thrower
889 F.3d 543 (Ninth Circuit, 2018)
PLIVA, Inc. v. Mensing
180 L. Ed. 2d 580 (Supreme Court, 2011)
Mut. Pharm. Co. v. Bartlett
570 U.S. 472 (Supreme Court, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Yahne v. A1A Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/yahne-v-a1a-inc-wawd-2023.